Logo

AbbVie Announces FDA's Acceptance of sNDA for PR for Imbruvica (ibrutinib) + Gazyva (Obinutuzumab)

Share this

AbbVie Announces FDA's Acceptance of sNDA for PR for Imbruvica (ibrutinib) + Gazyva (Obinutuzumab)

Shots:

  • The sNDA application is based on results of P-III iLLUMINATE (PCYC-1130) trial assessing Imbruvica (420) + Obinutuzumab (1000) vs chlorambucil (Days 1 & 15) + obinutuzumab (1000) over 6 cycles in patients with 1L CLL/SLL
  • The iLLUMINATE study demonstrated 1EP as PFS- which showed longer PFS rate for Imbruvica + Obinutuzumab vs chlorambucil + obinutuzumab- as per IRC
  • Imbruvica is novel PO BTKi qd therapy and has received nine FDA approvals across six diseases. The combination with anti-CD20 will be a novel CT-free combination if approved by the FDA for 1L CLL treatment

Ref: AbbVie | Image: Reeves Recruiting


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions